Lisata Therapeutics

Breakthrough Trials And Global Trends Will Redefine Oncology

AnalystHighTarget

Not Invested

Community Contributor

Published

16 Aug 25

AnalystHighTarget's Fair Value

US$32.00

92.6% undervalued

11 Sep

US$2.37

-20.5%

-6.0%

-20.5%

-6.0%

You can edit this narrative until Aug 16 9:13 PM. Then, changes will post as Updates.

Author's Valuation

US$3292.6% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$32

92.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

66.47%

Biotech revenue growth rate

8.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.79%

Calculation

US$2.19m

Earnings '28

176.46x

PE Ratio '28

US$387.02m

Market Cap '28

US$387.02m

Market Cap '28

9.93m

No. shares '28

US$38.96

Share Price '28

US$38.96 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$32.00

Fair Value '25